Why Is NEOGENOMICS INC (NEO) Stock Moving Today?

Why NEO stock is down today

NeoGenomics Inc. stock fell 13.72% to $16.51 on October 6, driven by the announcement of a leadership transition and the preliminary results for the third quarter of 2026. The CEO transition, which was disclosed in recent trading sessions, has led to investor uncertainty, despite the company’s preliminary results exceeding expectations. The stock’s sharp decline reflects market concerns over the short-term operational stability and the broader implications of the leadership change.

What Happened

The CEO transition at NeoGenomics was announced alongside the preliminary Q3 2026 results, which, while above consensus, failed to offset the negative sentiment from the executive change. The stock had already dropped 2% in a prior session following the pre-announcement and the leadership news. The move has raised questions about the continuity of the company’s strategic direction and operational execution. In response to the uncertainty, StoneX raised its price target for the stock to $20 from $16, and BTIG upgraded its rating to Buy from Neutral, citing a valuation gap. However, these actions did not prevent a significant intraday selloff.

What The Data Shows

The stock is currently trading near its 52-week low of $7.07 and has printed 44 fresh 52-week lows on October 6. The company has a market cap of $2.4 billion and remains unprofitable with a trailing twelve-month earnings per share of -0.40. Despite a 11.2% year-to-date revenue increase, the company’s net margin remains negative at -6.8%. The stock has high volatility, with a beta of 1.75. Recent insider activity includes a $321,000 sale by Chief Accounting Officer Aunan Greg D on August 4. Congressional activity includes purchases by Rep. Gilbert Cisneros and former President Donald J. Trump in the past 90 days.

What To Watch

The stock’s performance in the coming weeks will depend on how the market interprets the leadership transition and the full Q3 2026 earnings report. Investors should monitor the company’s guidance and any further analyst activity, as well as the broader biotech sector’s response to similar leadership changes.